vimarsana.com

Page 4 - புற்றுநோயியல் நிபுணர் லியோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CD40 drug before surgery can benefit patients with early-stage pancreatic cancer

Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.

Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors

Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors First-in-class NK Engager multifunctional antibody products can activate patients’ own NK cells or be combined with Cytovia’s off-the-shelf Universal iPSC-derived NK Cells April 12, 2021 11:11 ET | Source: Cytovia Therapeutics Cytovia Therapeutics Miami, Florida, UNITED STATES CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that it has filed two provisional composition of matter patent applications for its FLEX-NK® platform, consisting of NKp46-based NK cell e

Tiny SARS-CoV-2 protein may have big implications for future COVID-19 treatments

Tiny SARS-CoV-2 protein may have big implications for future COVID-19 treatments A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers. Using a novel toolkit of approaches, the scientists uncovered the first full structure of the Nucleocapsid (N) protein and discovered how antibodies from COVID-19 patients interact with that protein. They also determined that the structure appears similar across many coronaviruses, including recent COVID-19 variants making it an ideal target for advanced treatments and vaccines. They reported their results in Nanoscale. We discovered new features about the N protein structure that could have large implications in antibody testing and the long-term effects of all SARS-related pandemic viruses. Since it appears that the N protein is conserved across the variants of SARS-CoV-2 and SARS-CoV-1, therapeutics designed to target the N pr

Beloved Blacksburg cancer doctor reflects on 35 years of advances in care

“You are not going to die.” Jana Cranwell has a vivid memory of the day she heard those words. “I can still hear his voice,” she said of Dr. Harry McCoy, the Blacksburg oncologist who delivered the good news. “I can see his face.” It was 2012 and Cranwell had just had surgery for breast cancer when she found McCoy. “One thing I had known about him before I talked to him was that he told the truth,” Cranwell said. “If you were dying in two weeks, he would tell you.” She first heard of McCoy when he treated her husband’s aunt, who died of terminal cancer. It was McCoy who told her she had only weeks to live.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.